Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis

 
: Badorrek, Philipp; Hohlfeld, Jens M.; Krug, Norbert; Joshi, Abhijeet; Raut, Atul

:
Fulltext urn:nbn:de:0011-n-3666436 (309 KByte PDF)
MD5 Fingerprint: 44fcf3e71261781e7ce52c9e90741a5f
Created on: 17.11.2015


Annals of allergy, asthma, & immunology 115 (2015), No.4, pp.325-329.e1
ISSN: 0003-4738
ISSN: 1081-1206
ISSN: 1534-4436
English
Journal Article, Electronic Publication
Fraunhofer ITEM ()

Abstract
BACKGROUND: Allergic rhinitis (AR) poses a significant global burden with increasing prevalence. Although intranasal glucocorticosteroids are effective, older agents can have limiting side effects. S0597, a novel intranasal glucocorticosteroid, has demonstrated good safety and tolerability during preclinical and phase 1 studies. OBJECTIVE: To assess the clinical efficacy, safety, and tolerability of different doses of S0597 nasal spray vs placebo in patients with seasonal AR.
METHODS: This phase 2, randomized, double-blinded, placebo-controlled, parallel-group, single-center study randomized 159 patients 18 to 65 years old (mean age 37.8 years) with a positive skin prick test reaction for Dactylis glomerata to receive S0597 at 200, 400, or 800 mug/d or placebo for 15 days. On days 1 (baseline), 15, and 16, patients underwent a 4-hour pollen challenge to evaluate treatment efficacy measured by the change in total nasal symptom score (TNSS) from baseline to days 15 and 16 and changes in TNSS subscales and nasal secretion.
RESULTS: Statistically significant improvements in TNSS from baseline to days 15 and 16 were observed with all S0597 doses vs placebo (P = .0005 overall), with the greatest improvements observed in the highest-dose group (P < .0001). Significant decreases were observed in each S0597 dose group vs placebo for TNSS subscales and nasal secretion. Improvements in nasal secretion were related to dose, with the greatest decreases from baseline in the 800-mug/d group on days 15 and 16 (P < .0001).
CONCLUSION: Treatment with S0597 at 200, 400, and 800 mug/d by 2 divided doses for 2 weeks was safe and significantly more effective than placebo for improving nasal symptoms associated with grass pollen-induced seasonal AR in adults.
TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT01614691.

: http://publica.fraunhofer.de/documents/N-366643.html